{
  "docId": "019de076-7e9d-767a-a7eb-99a77c1645c5",
  "docSlug": "225408061c3ed04b028031d27cf2467f",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 62 slides",
  "authorId": "immix-biopharma",
  "authorName": "ImmixBio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 61,
  "pageCount": 62,
  "prevPage": 60,
  "nextPage": 62,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "The slide uses a 3-pillar framework to explain the platform, then maps these to specific drug candidates with detailed mechanism-of-action descriptions.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-7e9d-767a-a7eb-99a77c1645c5/61",
  "deckHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5",
  "deckJsonHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5.json",
  "deckAnchorHref": "/decks/019de076-7e9d-767a-a7eb-99a77c1645c5#slide-61",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.15,
        "x": 0.55,
        "y": 0.35
      },
      "kind": "image",
      "text": "Molecular structure diagrams for IMX-110, IMX-111, and IMX-120",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dbfb1cd0-8180-4202-b493-3ba12e623f93",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.35,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "list",
      "text": "System-Tissue Biology Model Development; Purpose-Built Physical Biochemistry Engine; Predictive Validation Framework",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9aa7bf10-a20a-4c46-86dd-74dced2d34b1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.55,
        "x": 0.4,
        "y": 0.35
      },
      "kind": "list",
      "text": "IMX-110: negatively-charged therapeutic, 1,200% increase in apoptosis; IMX-111: GLUT1 antibody targeting for CRC; IMX-120: Immune normalization for inflammatory bowel cells.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a021620f-dc5e-4690-a237-f955d91e4f0a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "title",
      "text": "TME Normalization™ Technology – SMARXT Tissue-Specific Platform Oncology Application",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "780e184f-51ee-4df9-a4d7-7c51e711d36e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "815eb6be-876e-4bde-a013-15ad0313d172",
      "evidence": "list/bullet: IMX-110: negatively-charged therapeutic, 1,200% increase in apoptosis; IMX-111: GLUT1 antibody targeting for CRC; IMX-120: Immune normalization for inflammatory bowel cells.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "3-pillar framework",
      "slug": null,
      "matchId": "3b32ccc9-693b-49c9-ab76-0af8653bc5f3",
      "evidence": "The slide explicitly labels the left column as '3 Pillars'.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 62,
      "from": 35,
      "beatId": "676eee44-bd9e-41af-b9af-35da1fc6b1d6",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "The document outlines the market opportunity, competitive landscape, and future plans for NXC-201 and other pipeline assets.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}